Indications and Purposes
| 1 Indications And Usage Trodelvy Is Indicated For The Treatment Of Adult Patients With Metastatic Triple-Negative Breast Cancer (Mtnbc) Who Have Received At Least Two Prior Therapies For Metastatic Disease. This Indication Is Approved Under Accelerated Approval Based On Tumor Response Rate And Duration Of Response [See Clinical Studies ( 14 )] . Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In Confirmatory Trials. Trodelvy Is A Trop-2-Directed Antibody And Topoisomerase Inhibitor Conjugate Indicated For The Treatment Of Adult Patients With Metastatic Triple-Negative Breast Cancer (Mtnbc) Who Have Received At Least Two Prior Therapies For Metastatic Disease. ( 1 ) This Indication Is Approved Under Accelerated Approval Based On Tumor Response Rate And Duration Of Response. Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In Confirmatory Trials. ( 1 , 14 ) |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Sacituzumab Govitecan |